Molecular Formula | C17H12F3NO4S |
Molar Mass | 383.34 |
Density | 1.56±0.1 g/cm3(Predicted) |
Boling Point | 505.8±50.0 °C(Predicted) |
Solubility | Soluble in DMSO |
pKa | 11.66±0.60(Predicted) |
Storage Condition | -20℃ |
Use | Belzutifan, also known as PT2977 and MK-6482, is HIF-2alpha inhibitor. PT2977 binds to and blocks the function of HIF-2alpha, thereby preventing HIF-2alpha heterodimerization and its subsequent binding to DNA. This results in decreased transcription and expression of HIF-2alpha downstream target genes, many of which regulate hypoxic signaling. This inhibits cell growth and survival of HIF-2alpha-expressing tumor cells. HIF-2alpha, the alpha subunit for the heterodimeric transcription factor HIF-2, is overexpressed in many cancers and promotes tumorigenesis. Belzutifan was approved in 2021 for treatment of von Hippel-Lindau disease under certain conditions。 |
Reference Show more | 1: Garje R, An JJ, Sanchez K, Greco A, Stolwijk J, Devor E, Rustum Y, Zakharia Y.Current Landscape and the Potential Role of Hypoxia-Inducible Factors andSelenium in Clear Cell Renal Cell Carcinoma Treatment. Int J Mol Sci. 2018 Dec1;19(12). pii: E3834. doi: 10.3390/ijms19123834. Review. PubMed PMID: 30513765. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.609 ml | 13.043 ml | 26.086 ml |
5 mM | 0.522 ml | 2.609 ml | 5.217 ml |
10 mM | 0.261 ml | 1.304 ml | 2.609 ml |
5 mM | 0.052 ml | 0.261 ml | 0.522 ml |